DXCM
Dexcom
Health Care · Health Care Equipment · US
$72.86
Data: 2026-05-15
✓ ETHICAL PASS

MODERATE MOAT
HIGH
Data Confidence: 100.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$23.8B
Total market value of the company
Trailing P/E
26.46
Premium valuation
Forward P/E
20.23
Based on estimated future earnings — lower means cheaper
Rev Growth
+15.0%
Year-over-year revenue change
Profit Margin
19.3%
How much profit the company keeps from each dollar of revenue
ROE
35.6%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$83.28
+14% from current price — median analyst estimate
Recommendation
STRONG_BUY
Consensus view from 25 analysts covering this stock
About Dexcom

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

https://www.dexcom.com

Country: United States Employees: 11,000 Industry: Medical Devices
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
21.9% PASS
Debt must be below 33% of total assets
Cash Ratio
3.4% PASS
Interest-bearing cash below 33% of assets
Receivables
33.7% PASS
Receivables below 49% of assets
Revenue Purity
2.4% PASS
Non-compliant revenue below 5% — any excess requires purification
Valuation
Fair Value Est.
$45.71
What our model estimates this business is worth per share
Margin of Safety
-59.4%
Trading above fair value — no margin of safety
Rating
OVERVALUED
Overall assessment combining ethics, valuation, and quality
Percentile
90.3th
Ranks in the top 10% of our 13,571 screened universe
Ethical Score
75.9
Valuation Score
44.5
Quality Score
81.3
Combined
64.1

Trading at $62, 35% above fair value of $46. Moderate competitive position. Passes all ethical screens. Ranks better than 56% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
MARKUP
Price trending up with increasing momentum
Sharpe Ratio
-0.289
Returns do not compensate for the risk — negative edge
Kelly Fraction
-0.0408
No positive edge detected — the data suggests staying out
Calmar Ratio
-0.438
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-25.0%
Historical annualised return based on price data
Max Drawdown
-57.0%
Largest peak-to-trough decline — the worst it has been
HMM State
SIDEWAYS
Price consolidating — no clear directional bias
Days in State
69
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
1.40
Moves slightly more than the broader market
52W High
$89.98
19% below the year high
52W Low
$54.11
35% above the year low
Avg Volume
4,460,646
Average daily shares traded — higher means easier to buy and sell
Short Ratio
4.3
Days it would take all short sellers to cover — higher means more crowded
Short % Float
5.5%
Moderate short interest
Div Yield
0.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$2.33
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
0.47
Conservative use of debt — low financial risk
Current Ratio
1.95
Healthy liquidity position
Quick Ratio
1.58
Like current ratio but excludes inventory — stricter test
Gross Margin
61.5%
Revenue left after cost of goods — higher means pricing power
Operating Margin
21.4%
Profit from core operations before interest and tax
Free Cash Flow
$1.1B
Positive — the business generates more cash than it spends
Revenue (TTM)
$4.8B
Total revenue over the last 12 months
Net Income
$930M
Profitable — the bottom line is positive
Analyst Coverage
Analysts
25
Target High
$112.00
Target Median
$83.28
Target Low
$65.00
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

55
NEUTRAL
Mixed insider activity. 0 purchases and 0 sales in the last 90 days — no clear directional signal. Politicians have been buying this name.
Date Insider Title Type Shares Value
2026-05-15 BROWN MICHAEL JON Officer 1,700 $101,847
2026-05-12 HELLER BRIDGETTE P Director 1,012 $60,730
2026-05-08 ALTMAN STEVEN R Director 5,037 —
2026-05-08 FOLETTA MARK G Director 5,731 —
2026-05-08 COLLINS RICHARD ALEXANDER Director 5,074 —
2026-05-08 AUGUSTINOS NICHOLAS Director 5,046 —
2026-04-15 BROWN MICHAEL JON Officer 1,700 $107,168
2026-03-16 BROWN MICHAEL JON Officer 1,700 $110,245
2026-03-06 SYLVAIN JEREME M Chief Financial Officer 48,774 —
2026-03-06 STERN SADIE Officer 39,019 —
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Political Trading Activity

Congressional trading disclosures involving this instrument

Date Politician Party Type Amount
2026-04-13 Ro Khanna Democrat Purchase 1K–15K
Source: Congressional disclosure filings. View all political trades at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.